Author:
Francis Kendra L.,Zheng Hengqi B.,Suskind David L.,Murphree Taylor A.,Phan Bao Anh,Quah Emily,Hendrickson Aarun S.,Zhou Xisheng,Nuding Mason,Hudson Alexandra S.,Guttman Miklos,Morton Gregory J.,Schwartz Michael W.,Alonge Kimberly M.,Scarlett Jarrad M.
Abstract
AbstractThe intestinal extracellular matrix (ECM) helps maintain appropriate tissue barrier function and regulate host-microbial interactions. Chondroitin sulfate- and dermatan sulfate-glycosaminoglycans (CS/DS-GAGs) are integral components of the intestinal ECM, and alterations in CS/DS-GAGs have been shown to significantly influence biological functions. Although pathologic ECM remodeling is implicated in inflammatory bowel disease (IBD), it is unknown whether changes in the intestinal CS/DS-GAG composition are also linked to IBD in humans. Our aim was to characterize changes in the intestinal ECM CS/DS-GAG composition in intestinal biopsy samples from patients with IBD using mass spectrometry. We characterized intestinal CS/DS-GAGs in 69 pediatric and young adult patients (n = 13 control, n = 32 active IBD, n = 24 IBD in remission) and 6 adult patients. Here, we report that patients with active IBD exhibit a significant decrease in the relative abundance of CS/DS isomers associated with matrix stability (CS-A and DS) compared to controls, while isomers implicated in matrix instability and inflammation (CS-C and CS-E) were significantly increased. This imbalance of intestinal CS/DS isomers was restored among patients in clinical remission. Moreover, the abundance of pro-stabilizing CS/DS isomers negatively correlated with clinical disease activity scores, whereas both pro-inflammatory CS-C and CS-E content positively correlated with disease activity scores. Thus, pediatric patients with active IBD exhibited increased pro-inflammatory and decreased pro-stabilizing CS/DS isomer composition, and future studies are needed to determine whether changes in the CS/DS-GAG composition play a pathogenic role in IBD.
Funder
National Institute of Diabetes and Digestive and Kidney Diseases
National Institute of General Medical Sciences
National Institute of Allergy and Infectious Diseases
National Institute on Aging
U.S. Department of Defense
Office of Research Central, University of Washington
Publisher
Springer Science and Business Media LLC
Reference78 articles.
1. Atlab, S. et al. The global, regional, and national burden of inflammatory bowel disease in 195 countries and territories, 1990–2017: A systematic analysis for the Global Burden of Disease Study 2017. Lancet Gastroenterol. Hepatol. 5, 17–30 (2019).
2. Chudy-Onwugaje, K. O., Christian, K. E., Farraye, F. A. & Cross, R. K. A state-of-the-art review of new and emerging therapies for the treatment of IBD. Inflamm. Bowel Dis. 25, 820–830 (2018).
3. Villablanca, E. J., Selin, K. & Hedin, C. R. H. Mechanisms of mucosal healing: Treating inflammatory bowel disease without immunosuppression?. Nat. Rev. Gastroenterol. https://doi.org/10.1038/s41575-022-00604-y (2022).
4. Cai, Z., Wang, S. & Li, J. Treatment of inflammatory bowel disease: A comprehensive review. Front. Med. 8, 765474 (2021).
5. Lichtenstein, G. R. et al. ACG clinical guideline: Management of Crohn’s disease in adults. Am. J. Gastroenterol. 113, 481–517 (2018).